VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM, which will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines. This collaboration supports IND/CTA-enabling activities and future clinical development, following encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
The cell line development is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies. VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. This conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window.
For more information, the full press release is available at https://ibn.fm/FCIlk. VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by transformative technologies and guided by quality-by-design principles, the company is advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL).
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. This announcement is significant because it marks a key step towards clinical development of a novel cancer therapy that could offer improved safety and efficacy for patients. The BiTAC platform's unique mechanism addresses a major limitation of current T-cell engagers, potentially expanding the therapeutic index and enabling treatment of a broader range of tumors.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These include factors beyond management's control as detailed in the Company's SEC filings. Undue reliance should not be placed on these statements, and all parties undertake no duty to update this information unless required by law.
